Fig. 1From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinomaEfficacy evaluation of 2-3 cycles of PD1 inhibitors in patients with Nasopharyngeal CarcinomaBack to article page